BNTX Stock Recent News

Truist initiated coverage of BioNTech with a Buy rating and $172 price target. BioNTech is an oncology company "at heart, even though it was the COVID vaccine that made it a household name," the analyst tells investors in a research note. The firm says that with the pandemic in the rear-view mirror, investor focus is increasingly shifting to BioNTech's oncology business. It says 2025 is set up with potentially stock-moving read-outs for key assets, presenting "ample opportunity" for BioNTech to grow into the price target.

Nearly one year ago, I made four predictions about the stock market in 2024. I thought the S&P 500 would generate positive returns but lower than in 2023.